Oculis Announces Oversubscribed $110 Million Financing Plan to Accelerate Development of Privosegtor

ZUG, Switzerland—Oculis Holding AG (Nasdaq: OCS; XICE: OCS), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases, announced pricing of an aggregate of 5,432,098 of its ordinary shares at $20.25 per share, raising $110 million in gross proceeds. Oculis intends to use the net proceeds from the financing to accelerate the development of its novel neuroprotective clinical candidate, Privosegtor, to be used in the treatment of acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes, the announcement noted. In early October, Oculis announced the advancement of Privosegtor into a registrational program for neuro-ophthalmology indications following a meeting with the U.S. Food and Drug Administration (FDA).